(in millions except per share amounts and percentages)
(unaudited)
RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP GROSS PROFIT
| Three Months Ended | Six Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| Gross profit, as reported | $ | 807.9 | $ | 827.5 | $ | 1,606.2 | $ | 1,642.7 | |||||||
| Share-based compensation expense | 6.0 | 5.2 | 12.4 | 10.1 | |||||||||||
| COVID-19 shelter-in-place restrictions on manufacturing activities | — | — | 2.8 | — | |||||||||||
| Non-GAAP gross profit | $ | 813.9 | $ | 832.7 | $ | 1,621.4 | $ | 1,652.8 | |||||||
| Non-GAAP gross profit percentage | 62.2 | % | 62.2 | % | 61.9 | % | 62.1 | % | |||||||
RECONCILIATION OF GAAP RESEARCH AND DEVELOPMENT EXPENSES TO NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES
| Three Months Ended | Six Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| Research and development expenses, as reported | $ | 199.8 | $ | 219.8 | $ | 397.8 | $ | 438.9 | |||||||
| Share-based compensation expense | (24.5 | ) | (22.3 | ) | (45.0 | ) | (41.8 | ) | |||||||
| Acquisition-related | — | — | — | (0.1 | ) | ||||||||||
| Non-GAAP research and development expenses | $ | 175.3 | $ | 197.5 | $ | 352.8 | $ | 397.0 | |||||||
| Non-GAAP research and development expenses as a percentage of net sales | 13.4 | % | 14.8 | % | 13.5 | % | 14.9 | % | |||||||
